Use of anakinra in severe COVID-19: A case report

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Filocamo, Giovanni, Mangioni, Davide, Tagliabue, Paola, Aliberti, Stefano, Costantino, Giorgio, Minoia, Francesca, Bandera, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211644/
https://www.ncbi.nlm.nih.gov/pubmed/32437934
http://dx.doi.org/10.1016/j.ijid.2020.05.026
_version_ 1783531484273967104
author Filocamo, Giovanni
Mangioni, Davide
Tagliabue, Paola
Aliberti, Stefano
Costantino, Giorgio
Minoia, Francesca
Bandera, Alessandra
author_facet Filocamo, Giovanni
Mangioni, Davide
Tagliabue, Paola
Aliberti, Stefano
Costantino, Giorgio
Minoia, Francesca
Bandera, Alessandra
author_sort Filocamo, Giovanni
collection PubMed
description Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).
format Online
Article
Text
id pubmed-7211644
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-72116442020-05-11 Use of anakinra in severe COVID-19: A case report Filocamo, Giovanni Mangioni, Davide Tagliabue, Paola Aliberti, Stefano Costantino, Giorgio Minoia, Francesca Bandera, Alessandra Int J Infect Dis Case Report Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra). The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020-07 2020-05-11 /pmc/articles/PMC7211644/ /pubmed/32437934 http://dx.doi.org/10.1016/j.ijid.2020.05.026 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Filocamo, Giovanni
Mangioni, Davide
Tagliabue, Paola
Aliberti, Stefano
Costantino, Giorgio
Minoia, Francesca
Bandera, Alessandra
Use of anakinra in severe COVID-19: A case report
title Use of anakinra in severe COVID-19: A case report
title_full Use of anakinra in severe COVID-19: A case report
title_fullStr Use of anakinra in severe COVID-19: A case report
title_full_unstemmed Use of anakinra in severe COVID-19: A case report
title_short Use of anakinra in severe COVID-19: A case report
title_sort use of anakinra in severe covid-19: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211644/
https://www.ncbi.nlm.nih.gov/pubmed/32437934
http://dx.doi.org/10.1016/j.ijid.2020.05.026
work_keys_str_mv AT filocamogiovanni useofanakinrainseverecovid19acasereport
AT mangionidavide useofanakinrainseverecovid19acasereport
AT tagliabuepaola useofanakinrainseverecovid19acasereport
AT alibertistefano useofanakinrainseverecovid19acasereport
AT costantinogiorgio useofanakinrainseverecovid19acasereport
AT minoiafrancesca useofanakinrainseverecovid19acasereport
AT banderaalessandra useofanakinrainseverecovid19acasereport

Ejemplares similares